BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1697314)

  • 21. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
    Seon BK
    Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates.
    Sivam G; Pearson JW; Bohn W; Oldham RK; Sadoff JC; Morgan AC
    Cancer Res; 1987 Jun; 47(12):3169-73. PubMed ID: 3495329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies.
    Quackenbush EJ; Letarte M
    J Immunol; 1985 Feb; 134(2):1276-85. PubMed ID: 3155538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
    Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
    Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the cytotoxic activity of the immunotoxins with different internalization rate.
    Tonevitsky AG; Agapov II; Mechetner EB; Ershova GV; Toptygin AYu ; Sarma T; Shamshiev AT; Pfueller U
    Biochem Mol Biol Int; 1993 Dec; 31(6):1059-69. PubMed ID: 8193589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
    Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
    Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
    Braslawsky GR; Edson MA; Pearce W; Kaneko T; Greenfield RS
    Cancer Res; 1990 Oct; 50(20):6608-14. PubMed ID: 2208123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
    Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
    J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
    Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW
    Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [ICO-35 monoclonal antibodies to the antigen of acute lymphoblastic leukemia].
    Baryshnikov AIu; Tupitsyn NN; Korotkova OV; Kadagidze ZG; Dostot E; Shmidt M; Boumsell L
    Eksp Onkol; 1989; 11(5):52-3. PubMed ID: 2529115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines.
    Goldmacher VS; Lambert JM; Young AY; Anderson J; Tinnel NL; Kornacki M; Ritz J; Blättler WA
    J Immunol; 1986 Jan; 136(1):320-5. PubMed ID: 2415623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
    Vuist WM; van Buitenen F; Hekman A; Melief CJ
    Cancer Res; 1990 Sep; 50(18):5767-72. PubMed ID: 1697500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
    Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia.
    Uckun FM; Myers DE; Ledbetter JA; Swaim SE; Gajl-Peczalska KJ; Vallera DA
    J Immunol; 1988 Mar; 140(6):2103-11. PubMed ID: 3126241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.